ArticlePloS one2025
Integrating genomic epidemiology and deep mutational scanning data for prevalence forecasting of SARS-CoV-2 Omicron lineages.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic-epidemiological analysis of 15 million SARS-CoV-2 genomes reveals accelerated fitness gain of JN.1 lineage.Virologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continuously circulates and the Omicron variants have mutated into over 2,500 lineages, predicting ensuing prevalent lineages and inflections of dominant lineages is of public health significance and study interest. Previous study has integrated genome to forecast lineage prevalence, yet overlooked the functional aspects of mutations; efforts to evaluate the functional effects of individual mutations have not extended to the lineage level. Here, we propose CoVPF, a model integrating both genomic epidemiology and deep mutational scanning (DMS) data for the receptor binding domain (RBD) of SARS-CoV-2 spike protein, to predict the prevalence of Omicron lineages. Retrospective validation demonstrated that CoVPF achieved 20.7% higher accuracy compared to previous study. Furthermore, we found that accounting for epistasis was critical, as ignoring epistasis led to a 43% decrease in forecasting accuracy. Case studies showed that CoVPF delivered more accurate and timely forecasts for lineage expansions and inflections such as EG.5.1 and XBB.1.5. CoVPF provides a paradigm for integrating in vitro functional readouts of the virus and accounting for combinatorial effects of mutations in support of public health efforts in lineage prevalence forecasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.